George Demetri, MD, professor of medicine, Harvard Medical School, director of the Sarcoma Center, Dana Farber Brigham Women's Cancer Center, on the mutagenic properties of dacarbazine.
George Demetri, MD, professor of medicine, Harvard Medical School, director of the Sarcoma Center, Dana Farber Brigham Women's Cancer Center, on the mutagenic properties of dacarbazine. Demetri says recent studies have revealed that dacarbazine is much more useful in the treatment of leiomyosarcomas than initially thought.
Demetri adds that the mutagenic properties of dacarbazine are so prevalent that he hopes future studies might be able to take advantage of them. He further elaborates that the mutagenic properties of the treatment are so strong that they could potentially form new, potentially useful neoantigens on sarcoma cells. Demetri believes that dacarbazine's unique properties may play an additional role in finding ways to utilize chemotherapy as a senstizer to immuno-oncologic approaches like checkpoint inhibition.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More